Back to Journals » Therapeutics and Clinical Risk Management » Volume 6

Ropinirole in restless legs syndrome and periodic limb movement disorder

Authors Erichsen D, Ferri R, Gozal D

Published 14 April 2010 Volume 2010:6 Pages 173—182

DOI https://doi.org/10.2147/TCRM.S6717

Review by Single-blind

Peer reviewer comments 3


Daniel Erichsen1, Raffaelle Ferri2, David Gozal1

1Department of Pediatrics, University of Chicago, Chicago, IL, USA; 2Department of Neurology, Oasi Institute IRCCS, Troina, Italy

Abstract: Restless legs syndrome and periodic limb movement disorder of sleep are now recognized as prevalent, distinct, yet overlapping disorders affecting all age groups. Although delineation of the mechanisms underlying these disorders continues to be the focus of very intense research efforts, it has become apparent that there is a prominent role for dopaminergic agents in the clinical management of these patients. Among the various dopaminergic drugs, ropinirole has undergone relatively intense and critical scrutiny, and appears to provide a safe and efficacious treatment option for patients with these two conditions. The more recent development of a controlled formulation for this drug is likely to yield additional benefits such as improved adherence and reduced fluctuations in daytime and nighttime symptoms. However, there is not enough evidence at this time to support such assumption.

Keywords: dopaminergic drugs, restless legs syndrome, ropinirole, period limb movement disorder

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]